ABSTRACT
The benefits of feeding avilamycin (Surmax/Maxus, Elanco Animal Health) to broiler chickens were demonstrated in a floor pen study (two trials) in which avilamycin was fed at 10 ppm in a 45-day growout. Final live weight of broilers fed avilamycin was significantly (P < or = .01) heavier (90 g) than that of control broilers fed for an equal number of days. Feed conversion was numerically but not significantly improved by avilamycin. Dressing percentage (hot eviscerated carcass weight/live weight) of broilers fed avilamycin was significantly improved (P < or = .01) relative to that of control broilers fed for an equal number of days.
Subject(s)
Anti-Bacterial Agents/pharmacology , Chickens/growth & development , Oligosaccharides/pharmacology , Animal Feed/analysis , Animals , Body Composition/drug effects , Diet/veterinary , Female , Male , Muscle, Skeletal/anatomy & histology , Muscle, Skeletal/drug effects , Weight Gain/drug effectsABSTRACT
The antimicrobial susceptibility of 88 isolates of Moraxella bovis of Argentine origin was evaluated for 12 antimicrobials by broth microdilution procedures. The isolates had a minimum inhibitory concentration (MIC90) of < or = 0.06 microg/mL to enrofloxacin; < or = 0.12 microg/mL to ceftiofur; < or = 0.25 microg/mL to ampicillin; < or = 0.5 microg/mL to florfenicol and gentamicin; < or = 1.0 microg/mL to tilmicosin, erythromycin, and oxytetracycline; < or = 4.0 microg/mL to tylosin; < or = 8.0 microg/mL to spectinomycin; < or = 0.25/4.75 microg/mL to trimethoprim/sulfamethoxazole; and > or = 32 microg/mL to lincomycin. Modal MIC values for these antimicrobials were as follows: enrofloxacin, 0.03 microg/mL; ceftiofur, 0.06 pg/mL; ampicillin, 0.25 microg/mL; florfenicol, gentamicin, erythromycin, and oxytetracycline, 0.5 microg/mL; tilmicosin, 1.0 microg/mL; tylosin and spectinomycin, 4.0 microg/mL; lincomycin and erythromycin, 16 microg/mL; and trimethoprim/ sulfamethoxazole, < or = 0.25/4.75 microg/mL. These data show that all antimicrobials except lincomycin have MICs suggestive of sensitivity in vitro, though confirmation of clinical efficacy can only be properly assessed based on pharmacologic and/or clinical data to support the MIC values.